Patents by Inventor Linglong Kong

Linglong Kong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
    Publication number: 20230083012
    Abstract: Provided are dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.
    Type: Application
    Filed: July 30, 2020
    Publication date: March 16, 2023
    Inventors: Yimin JIANG, Zhanling CHENG, Gang DENG, Zhiguo LIU, Chao LIANG, Jianping WU, Linglong KONG, Xiangjun DENG, Yanping XU
  • EXO-AZA SPIRO INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20230039917
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: May 2, 2022
    Publication date: February 9, 2023
    Inventors: Xuedong DAI, Olivier Alexis Georges QUEROLLE, Daniel Jason KROSKY, Wei CAI, Liqiang FU, Linglong KONG, Yingtao LIU, Zhao-Kui WAN, Barbara MORSCHHÄUSER GEB. HERKERT, Vineet PANDE, James Patrick EDWARDS, Aaron Nathaniel PATRICK, Patrick René ANGIBAUD, Virginie Sophie PONCELET
  • HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
    Publication number: 20230002408
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Application
    Filed: December 18, 2020
    Publication date: January 5, 2023
    Inventors: Gang DENG, Zhanling CHENG, Zhiguo LIU, Chao LIANG, Jianping WU, Linglong KONG, Xiangjun DENG, Yimin JIANG, Yanping XU
  • DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
    Publication number: 20220281865
    Abstract: Provided herein are dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.
    Type: Application
    Filed: July 30, 2020
    Publication date: September 8, 2022
    Inventors: Yimin JIANG, Zhanling CHENG, Gang DENG, Zhiguo LIU, Chao LIANG, Jianping WU, Linglong KONG, Xiangjun DENG, Yanping XU
  • DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES
    Publication number: 20220267313
    Abstract: Provided herein are dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.
    Type: Application
    Filed: July 30, 2020
    Publication date: August 25, 2022
    Inventors: Yimin JIANG, Zhanling CHENG, Gang DENG, Zhiguo LIU, Chao LIANG, Jianping WU, Linglong KONG, Xiangjun DENG, Yanping XU
  • Exo-aza spiro inhibitors of menin-MLL interaction
    Patent number: 11396517
    Abstract: Provided are compounds of Formula (I), pharmaceutical compositions comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: July 26, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Xuedong Dai, Olivier Alexis Georges Querolle, Daniel Jason Krosky, Wei Cai, Liqiang Fu, Linglong Kong, Yingtao Liu, Zhao-Kui Wan, Barbara Morschhäuser Geb. Herkert, Vineet Pande, James Patrick Edwards, Aaron Nathaniel Patrick, Patrick René Angibaud, Virginie Sophie Poncelet
  • RE-IDENTIFICATION RISK ASSESSMENT USING A SYNTHETIC ESTIMATOR
    Publication number: 20220050917
    Abstract: A risk of re-identifying a particular individual associated with a record in a dataset can be assessed by synthesizing a dataset from a dataset to be shared and then sampling a synthetic microdata dataset from the synthetic dataset. The synthetic dataset and the synthetic microdata dataset can then be used to estimate the risk of re-identifying an individual from the dataset to be shared.
    Type: Application
    Filed: August 12, 2021
    Publication date: February 17, 2022
    Inventors: Yangdi JIANG, Bei JIANG, Linglong KONG, Khaled EL EMAM
  • TERTIARY AMIDES AND METHOD OF USE
    Publication number: 20190119200
    Abstract: Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 25, 2019
    Inventors: Lawrence A. Black, William H. Bunnelle, Da Chen, Bruce Clapham, David A. Degoey, Xiangjun Deng, Liqiang Fu, Lisa A. Hazelwood, Linglong Kong, Qingyu Lang, Chih-Hung Lee, Mingfeng Li, Greta L. Lundgaard, Meena V. Patel, Ruihong Tao, Lin Zhang, Qingwei Zhang, Qiangang Zheng, Wei Zhu